Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06409221
Other study ID # 3.5
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date May 1, 2024
Est. completion date December 31, 2025

Study information

Verified date May 2024
Source Concr
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: Despite improvements in the treatment of Triple Negative Breast Cancer (TNBC), the cancer returns in half of the women and shockingly 40% are dead within 5 years of their initial cancer diagnosis. There is an urgent need to identify reliable biomarkers of response for chemotherapy and immunotherapy. Study Aims: To update Concr's existing predictive algorithms specifically for use in women newly diagnosed with TNBC. The plan is develop technology which will predict which drug the cancer will respond best to, treatment A vs. treatment B AND how the individual's prognosis could change if treatment A is chosen overtreatment B. Study Design: The VISION study is a clinical study looking back in time (retrospective study), specifically focusing on women who were previously diagnosed with early Triple Negative breast cancer and received chemotherapy followed by curative breast surgery. The plan is to collect historical clinical data and previously collected cancer biopsy samples from up to 200 women in order to update Concr's existing treatment prediction algorithms. Hence there are no extra research biopsies needed in order to participate in the Study. Study Sites: UK and Australia Study Funding: This study is funded by the a Techbio company called Concr with support from Innovate UK (UK Government funding).


Description:

VISION is a commercially sponsored clinical trial designed to be a retrospective, observational non-CTIMP research study which will collect archival tumour samples from participants previously treated with chemotherapy +/- immunotherapy for early Triple Negative Breast Cancer (TNBC). Current Study design: VISION currently has 2 retrospective patient cohorts: 1. Arm A: Patients treated with neoadjuvant chemotherapy who had a complete pathological response (n = 100), 2. Arm B: Patients treated with neoadjuvant chemotherapy who had a residual cancer burden (n=100). Planned study design: Include a prospective arm, Arm C to test feasibility of generating treatment predictions in real time. Study sites: UK and Australia Study timelines: 2 years UK start date: April 26th, 2024 Datasets planned for collection are: 1. Clinical data about the individual, cancer stage at diagnosis, cancer treatment, treatment response and clinical outcome, 2. Genomic data from diagnostic breast cancer samples +/- surgical samples, 3. Whole Slide Imaging data from tumour sections. Planned Next Generation Sequencing of tumours: 1. RNA sequencing 2. DNA sequencing 3. Other NGS approaches or -OMICS (subject to tissue availability) Planned tissue collection: Tissue type: Archival FFPE samples Diagnostic samples (before chemotherapy) +/- surgical samples (after chemotherapy) Planned technology development: Existing Concr technology which predicts cancer response, currently pan-cancer, in the early Triple Negative Breast Cancer population A key objective is to demonstrate that accurate prediction of therapeutic response for chemotherapy, specifically anthracyclines, taxanes, platinums, anti-metabolites with/without immunotherapy.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 200
Est. completion date December 31, 2025
Est. primary completion date June 1, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - Age: = 18 years - Mental Capacity: Individual should be able to give informed consent, if alive - Triple Negative Breast Cancer (TNBC) - Oestrogen receptor (ER) negative with an Allred score of = 2 or, equivalent pathology scoring system e.g., =10% (0 - 10%) tumour nuclei staining - HER2 negative: 1+ on immunohistochemistry or 2+ immunohistochemistry and FISH/D-Dish negative - Progesterone receptor (PgR) negative = PgR score of =2 or equivalent pathology scoring system e.g., =10% (0 - 10%) tumour nuclei staining - Androgen receptor (AR) status (if known): negative or positive - TNBC phenotype: HER2 negative tumours with borderline ER or PgR scoring on immunohistochemistry e.g., ER 3/8 and PgR 0/3 negative which were managed as early TNBC can be included but should be discussed on a case-by-case basis prior to study registration with Principal Investigator. - Lymph node involvement: Lymph node negative or positive; any number including clinical/pathological N3 involvement (TNM staging = V.8.0) - Cancer Staging: Stage 2 or stage 3 breast cancer - Treated considered standard of care neoadjuvant chemotherapy: an anthracycline, a taxane, an alkylating agent, +/- a platinum, +/- immunotherapy - Available archival tissue samples Key Exclusion Criteria: - Stage IV de novo metastatic breast cancer are not eligible - Stage I breast cancers are not eligible - Women who were diagnosed with more than one cancer type within 3 years of the breast cancer diagnosis of TNBC are not eligible - Received neoadjuvant radiotherapy - Received neoadjuvant endocrine treatment - Women pregnant at the time of the TNBC diagnosis - Significant medical co-morbidities which could have influenced the participant's prognosis are excluded. Examples include cardiac failure, moderate - severe renal failure, active hepatitis, HIV, active TB, ischaemic heart disease etc.

Study Design


Intervention

Other:
Non-interventional study, Observational only
Observational study only, there are no planned interventions.

Locations

Country Name City State
United Kingdom Royal Marsden Hospital London

Sponsors (4)

Lead Sponsor Collaborator
Concr Durham University, Institute of Cancer Research, United Kingdom, Royal Marsden NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Validate accuracy of the Breast cancer therapeutic response predictive algorithm for predicting pathological complete response (pCR) in the early TNBC population treated with neoadjuvant chemotherapy. 24 months
Primary Identify women with chemotherapy sensitive and chemotherapy resistant breast cancers. 24 months
Secondary Predict Overall Survival for women diagnosed with early TNBC following neoadjuvant chemotherapy. 24 months
Secondary Validate algorithm for predicting changes in tumour size in response to neoadjuvant treatment. 24 months
Secondary Develop a risk of recurrence score for predicting the future probability of developing distant metastases in the early Triple Negative population. 24 months
Secondary Exploratory biomarker analyses of chemotherapy resistant tumour tissue post neoadjuvant chemotherapy. 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05174832 - Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Withdrawn NCT03634150 - Safety and Efficacy of IV Nerofeā„¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer Phase 1/Phase 2
Recruiting NCT03348098 - Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer Phase 2
Completed NCT04032080 - LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Withdrawn NCT02427581 - Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy Phase 1
Recruiting NCT03165487 - Comparison of the Breast Tumor Microenvironment
Completed NCT02225470 - Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes Phase 3
Recruiting NCT04452370 - Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer Phase 2
Terminated NCT04123704 - Sitravatinib in Metastatic Breast Cancer Phase 2
Recruiting NCT04758780 - Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients Phase 2
Withdrawn NCT04268693 - Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer
Withdrawn NCT03982173 - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors Phase 2
Not yet recruiting NCT02685657 - Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer Phase 2
Terminated NCT01918306 - GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer Phase 1/Phase 2
Completed NCT01276899 - Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients
Completed NCT00998036 - Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors Phase 1
Recruiting NCT05309655 - Cardiac Outcomes With Near-Complete Estrogen Deprivation Early Phase 1
Active, not recruiting NCT03267316 - A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors Phase 1/Phase 2